Summary by Moomoo AI
HOOKIPA Pharma, a clinical-stage biopharmaceutical company, reported a net loss of $81.6 million for the year ended December 31, 2023, compared to a net loss of $64.9 million for the previous year. The company's accumulated deficit reached $369.3 million as of December 31, 2023. Despite the losses, HOOKIPA Pharma highlighted progress in its oncology and infectious disease pipelines. The HB-200 program, targeting HPV16+ head and neck cancers, showed a 42% objective response rate in a Phase 2 trial, and preparations for a Phase 2/3 trial are underway. The HB-700 program, in partnership with Roche, is set for an IND submission in Q2 2024, although Roche has terminated the collaboration agreement, effective April 25, 2024. HOOKIPA's infectious disease efforts include the HB-400 program for Hepatitis B and the HB-500 program for HIV, both...Show More